Publication: 4296

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.
      Google Scholar   
Citation:
Cell Rep Med 102154
Year:
2025
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Other-NOS
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
GSK/Novartis  
Grants:
U10CA180821, U10CA180882, U24CA196171, U24CA270823, U24CA210986, U01CA214125, U24CA210979, U24CA210954, RR160027, P50 CA186784-06), T32CA203690, 1S10OD028671-01, P50 CA186784-06, RR140027 (CPRIT Scholar in Cancer Research)  
Corr. Author:
 
Authors:
                                                               
Networks:
LAPS-NC007, METROMIN, NJ032, TX041   
Study
CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: